What's Happening?
Tenpoint Therapeutics has submitted a Marketing Authorization Application (MAA) to the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for YUVEZZI, a dual-agent eye drop designed to treat presbyopia. This condition, affecting close-up
vision, impacts approximately 128 million people in the US and 30 million in the UK. The submission follows the product's approval by the US FDA in January 2026. Supported by positive data from two Phase 3 studies, YUVEZZI has shown significant improvement in near vision with a single daily drop. The application is part of Tenpoint's strategy to expand its market presence globally.
Why It's Important?
The submission of YUVEZZI for approval in the UK represents a significant step in addressing the widespread issue of presbyopia, which affects a large portion of the aging population. If approved, the treatment could offer a convenient, non-invasive solution for millions, potentially reducing the need for reading glasses or other corrective measures. This move also highlights the growing trend of pharmaceutical companies seeking international regulatory approvals to expand their market reach and address global health needs.
